Coronavirus (COVID-19) Infection Survey, UK: 9 July 2021

• In England, the percentage of people testing positive for coronavirus (COVID-19) continued to increase in the week ending 3 July 2021; we estimate that 332,900 people within the community population in England had COVID-19 (95% credible interval: 296,700 to 368,700), equating to around 1 in 160 people.

• In Wales, the percentage of people testing positive continued to increase in the week ending 3 July 2021; we estimate that 9,000 people in Wales had COVID-19 (95% credible interval: 5,300 to 13,600), equating to around 1 in 340 people.

• In Northern Ireland, the percentage of people testing positive increased in the week ending 3 July 2021; we estimate that 6,100 people in Northern Ireland had COVID-19 (95% credible interval: 3,000 to 10,500), equating to around 1 in 300 people.

• In Scotland, the percentage of people testing positive continued to increase in the week ending 3 July 2021; we estimate that 53,200 people in Scotland had COVID-19 (95% credible interval: 41,300 to 67,000) equating to around 1 in 100 people.

• In the week ending 3 July 2021, cases that are compatible with the Delta variant B.1.617.2 have continued to increase in England, Wales and Scotland, and increased in Northern Ireland; the Delta variant is now the most common variant across the UK.

About this bulletin

In this bulletin, we refer to the number of current COVID-19 infections within the community population; community in this instance refers to private residential households and it excludes those in hospitals, care homes and/or other institutional settings. In institutional settings, rates of COVID-19 infection are likely to be different. More information about the coronavirus pandemic from the Office for National Statistics (ONS) and other sources can be found in our latest insights.

The positivity rate is the percentage of people who have tested positive for COVID-19 at a point in time. We use current COVID-19 infections to mean testing positive for SARS-CoV-2, with or without having symptoms, on a swab taken from the nose and throat. This is different to the incidence rate, which is a measure of only the new polymerase chain reaction (PCR)-positive cases in a given time period.

All analysis was produced with our research partners at the University of Oxford.

Early management information from the Coronavirus (COVID-19) Infection Survey is made available to government decision-makers to inform their response to COVID-19. Occasionally we may publish figures early if it is considered in the public interest. We will ensure that we pre-announce any ad hoc or early publications as soon as we can. These will include supporting information where possible to aid user understanding. This is consistent with guidance from the Office for Statistics Regulation (OSR).

How the data in this bulletin can be used

The data can be used for:

• estimating the number of current positive cases in the community, including cases where people do not report having any symptoms

• identifying differences in numbers of positive cases between different regions

• estimating the number of new cases and change over time in positive cases

The data cannot be used for:

• measuring the number of cases and infections in care homes, hospitals and/or other institutional settings

• providing information about recovery time of those infected

In the week ending 3 July 2021, the percentage of people testing positive continued to increase in England, Wales and Scotland. In Northern Ireland, over the same week, the percentage of people testing positive started to increase.

These estimates are based on statistical modelling of the trend in rates of positive nose and throat swab results. The ratios presented are rounded to the nearest 10. Because of lower positivity rates, caution should be taken in over-interpreting any small movements in the latest trends.

Figure 1: In the week ending 3 July 2021, the percentage of people testing positive increased across the UK

Estimated percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs from 27 April 2020 to 3 July 2021

Notes:

1. All estimates are subject to uncertainty, given that a sample is only part of the wider population. The model used to provide these estimates is a Bayesian model: these provide 95% credible intervals. A credible interval gives an indication of the uncertainty of an estimate from data analysis. 95% credible intervals are calculated so that there is a 95% probability of the true value lying in the interval.
2. Official reported estimates are plotted at a reference point believed to be most representative of the given week.
3. The official estimate presents the best estimate at that point in time. Modelled estimates are used to calculate the official reported estimate. The model smooths the series to understand the trend and is revised each week to incorporate new test results, providing the best indication of trend over time.
4. Survey fieldwork for the pilot study began in England on 26 April 2020. In Wales, fieldwork began on 29 June 2020, in Northern Ireland fieldwork began on 26 July 2020 and in Scotland fieldwork began on 21 September 2020.

Download the data

.xlsx

About our estimates

Our headline estimates of the percentage of people testing positive in England, Wales, Northern Ireland and Scotland are the latest official estimates. We include different measures to support our estimation and this section outlines the appropriate uses of all the approaches.

Official estimates should be used to understand the positivity rate for a single point in time. This is based on the modelled estimate for the latest week and is our best and most stable estimate, used in all previous outputs. The modelled estimate is more suited to understand the recent trend. This is because the model is regularly updated to include new test results and smooths the trend over time. These modelled estimates can be found in the accompanying datasets.

The estimates for non-overlapping 14-day periods (which underpin our modelled official estimates) and the unweighted sample counts are included in the accompanying datasets. These estimates are produced using a different method of weighting to the model and are available for people who wish to compare infection levels over time in this way. Information about how the modelled and 14-day non-overlapping estimates are calculated can be found in our methods article.

All estimates presented in this bulletin are provisional results. As swabs are not necessarily analysed in date order by the laboratory, we have not yet received test results for all swabs taken on the dates included in this analysis. Estimates may therefore be revised as more test results are included.

The overall national picture for England is a result of the trends across regions. During the week ending 3 July 2021, the highest percentage of people testing positive was observed in the North East and North West.

In the week ending 3 July 2021, the percentage of people testing positive has increased in all regions.

Figure 2: The percentage of people testing positive increased in all English regions in the week ending 3 July 2021

Estimated percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs, daily, by region from 23 May to 3 July 2021, England

Notes:

1. All results are provisional and subject to revision.
2. These statistics refer to infections reported in the community, by which we mean private households. These figures exclude infections reported in hospitals, care homes and/or other institutional settings.
3. The percentage of people testing positive by region was calculated using a similar modelling approach to the national daily estimates in Section 2: Percentage of people who had COVID-19 in England, Wales, Northern Ireland and Scotland.
4. The analysis is conducted over a six-week period, which means specific positive cases move into and then out of the sample. This causes variability between estimates over time, which is expected given the lower number of positive tests within each region, compared with England as a whole.
5. The credible intervals widen slightly at the end as there is a delay between the swab being taken and reporting of results.

Download the data

.xlsx

Age analysis by category for England

Our age categories separate children and young people by school age:

• "age two years to school Year 6" includes those children in primary school and below

• "school Year 7 to school Year 11" includes those children in secondary school

• "school Year 12 to age 24 years" includes those young adults who may be in further or higher education

This means that 11 to 12-year-olds and 16 to 17-year-olds have been split between different age categories depending on whether their birthday is before or after 1 September.

In the week ending 3 July 2021, rates have increased in all age groups.

Figure 3: The percentage of people testing positive increased in all age groups in the week ending 3 July 2021 in England

Estimated percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs, daily, by age group from 23 May to 3 July 2021, England

Notes:

1. All results are provisional and subject to revision.
2. These statistics refer to infections reported in the community, by which we mean private households. These figures exclude infections reported in hospitals, care homes and/or other institutional settings.

Download the data

.xlsx

We are unable to produce the same grouped analysis as presented in Figure 3 for the devolved administrations because of smaller sample sizes within each age group. We are able to produce analysis on positivity by single year of age for Wales, Northern Ireland and Scotland using a different model and these can be found in the following section and datasets that accompany this bulletin.

Estimates for non-overlapping 14-day periods (which underpin our modelled estimates) by age group are available in our accompanying dataset and are provided as an alternative measure over time for context.

Age analysis by single year of age over time by country

In this section we present modelled daily estimates of the percentage testing positive for COVID-19 by single year of age over time for all four UK countries: England, Wales, Northern Ireland and Scotland from 23 May 2021. These estimates use a different method to the grouped age analysis presented previously and are therefore not comparable.

Further analysis on age for Wales, Northern Ireland and Scotland is published by their respective statistical agencies. Analysis for Wales is published in English and Welsh.

Figure 4 shows the percentage of people testing positive for COVID-19 by single year of age from 23 May to 3 July 2021, for each of the four UK countries. Because of lower positivity rates during some of this period, caution should be taken in over-interpreting small movements in positivity day to day.

Figure 4: The percentage of people testing positive for COVID-19 by single year of age over time for the four UK countries

Estimated percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs, daily, by single year of age from 23 May to 3 July 2021, UK

Notes:

1. All results are provisional and subject to revision.
2. These statistics refer to infections reported in the community, by which we mean private households. These figures exclude infections reported in hospitals, care homes and/or other institutional settings.
3. These estimates use a different method to previous modelled daily estimates of the percentage testing positive by age group for England and are therefore not comparable.

Download the data

.xlsx

The incidence rate is a measure of new polymerase chain reaction (PCR)-positive cases in a given time period. We regularly review our methods and survey design as part of our ongoing quality assurance process. We have recently completed our review and are now including estimates of the incidence rate in our accompanying datasets.

Our incidence method uses several weeks' data to provide the latest estimate of new infections. Following our review, we have changed the reference date used for our official estimates of incidence of PCR-positive cases to 14 days prior to the end of the positivity reference date, with credible intervals provided until 7 days after the incidence reference date. Previously the incidence reference date was 10 days prior to the end of the positivity reference date. This change was necessary as estimates later than this date are more likely to change as we receive additional data. Estimates of incidence are therefore not the latest figure as there is a time lag of two weeks between the incidence estimate and the positivity estimate.

While we believe that the estimates are useful, they can be volatile and subject to change as more data become available. This is particularly the case with the most recent estimates so it is important to be cautious when using them. When incidence is low, it may not be possible to produce a reliable estimate. In these instances we recommend focusing on the upper credible interval, which gives an upper bound to the incidence of new infections. For more information on how we calculate estimates of incidence please see COVID-19 Infection Survey: methods and further information.

In the week ending 19 June 2021, the number of new PCR-positive COVID-19 cases appeared to be increasing across the UK.

The World Health Organisation (WHO) have suggested new names for Variants of Concern and Variants of Interest.

Variants of concern

Alpha

Variant B.1.1.7, first identified in the UK.

Beta

Variant B.1.351, first identified in South Africa.

Gamma

Variant P.1, first identified in Brazil.

Delta

Variant B.1.617.2, first identified in India.

Variants of interest

Eta

Variant B.1.525, first identified in Nigeria.

The Alpha variant (B.1.1.7) of coronavirus (COVID-19) identified in the UK in mid-November 2020 has changes in one of the three genes that COVID-19 swab tests detect, known as the S-gene. This means that in cases compatible with this variant, the S-gene is not detected by the current test. Therefore Alpha (B.1.1.7) has the pattern ORF1ab+N (S-gene negative) in our main variant analysis.

Other variants - including both Delta (B.1.617.2) and Beta (B.1.351) - are positive on all three genes, with the pattern ORF1ab+S+N. Based on recent information from genomic sequencing and national testing programmes, it is likely that most ORF1ab+S+N cases in the UK will be the Delta variant. Therefore, if there is an increase in the prevalence of the Delta strain, this will show up in our analysis as an increase in our category "compatible with the Delta variant". Our main variant analysis can differentiate between these two groups of variants (ORF1ab+N positive or ORF1ab+S+N positive) but cannot differentiate between variants that have the same gene pattern for the three genes that COVID-19 swab tests detect. More information on individual variants and where they were first detected is available on the government variant dashboard.

Other variants, including Eta (B.1.525), also have the same pattern of gene positivity as Alpha (B.1.1.7). At present these are rare in the UK so we describe this group as compatible with the Alpha variant, but we will continue to keep this under review. The percentage of people testing positive by different variants are provided in the accompanying technical dataset.

Since the end of May, infections compatible with the Delta variant have been the most common in England. In the week ending 3 July 2021, the percentage of people testing positive whose results are compatible with the Delta variant (B.1.617.2) continued to increase in England, Wales and Scotland and have started to increase in Northern Ireland.

In the week ending 3 July 2021, the percentage of people testing positive whose results are compatible with the Alpha variant (B.1.1.7) remained low in England and Wales while the trend was uncertain in Northern Ireland and Scotland.

Figure 5: The percentage of people testing positive whose results are compatible with the Delta variant increased across the UK in the week ending 3 July 2021

Modelled percentage of cases compatible with the Alpha variant, compatible with the Delta variant and where the virus was too low for the variant to be identifiable, based on nose and throat swabs, daily, from 23 May to 3 July 2021, UK

Notes:

1. All results are provisional and subject to revision.
2. These statistics refer to infections reported in the community, by which we mean private households. These figures exclude infections reported in hospitals, care homes and/or other institutional settings.
3. Alpha variant compatible positives are defined as those that are positive on the ORF1ab-gene and N-gene, but not the S-gene. Delta variant compatible positives are defined as those that are positive on the ORF1ab, N-gene and S-gene. Positives where the virus is too low for the variant to be identifiable are defined as those that are positive with all other gene patterns. These definitions are regardless of cycle threshold (Ct) value.
4. Data should be treated with caution. There are uncertainties given that not all cases that are positive on the ORF1ab and N-gene will be the Alpha variant, and not all cases that are positive on all three of the ORF1ab, N-gene and S-gene will be the Delta variant.
5. Cases where the virus is too low for the variant to be identifiable are likely to be people very recently infected or those who are recovering from their infection; people who get new infections after vaccination may also be in this group.

Download the data

.xlsx

Each test goes through a number of cycles before a positive result is detectable. If there is a high quantity of the virus present, a positive result will be identified after a low number of cycles. However, if there is only a small amount of the virus present, then it will take more cycles to detect it.

The number of cycles is measured as a "cycle threshold", known as a Ct value. These values are used as a proxy for the quantity of the virus, also known as the viral load. The higher the viral load, the lower the Ct value. These values are helpful for monitoring the strength of the virus and for identifying patterns that could suggest changes in the way the virus is transmitting. The Ct values of COVID-19 positive tests are provided in the technical dataset that accompanies this bulletin.

We try to read all letters of the virus' genetic material for every positive nose and throat swab with sufficient virus to do so (Ct less than 30). This is called whole genome sequencing. Positive samples are hand-picked at the testing centre and shipped to a sequencing lab, after which they are sequenced and the genetic data processed. Sequencing is not successful on all these samples, or only part of the genome is sequenced. This is especially so for the higher Ct values, which are common in our data as we often catch people early or late in infection when viral loads tend to be lower (and hence Ct values are higher). Where we successfully sequence over half of the genome, we use the sequence data to work out which type of variant is present in each virus. This method can tell us which variant might be responsible for any potential increase in cases which are either "compatible with the Delta variant" or "compatible with the Alpha variant". However, because we cannot get a sequence from every positive result, there is more uncertainty in these estimates.

These data are provided in the accompanying technical dataset using the international standard labels.

Genome sequencing takes longer to produce results, so the genome sequencing results relate to an earlier time period than our most recent positivity data. Our most recent results from genome sequencing show that in the four weeks up to the week ending 27 June 2021, the majority (92%) of sequences obtained were Delta (B.1.617.2) with Alpha (B.1.1.7) comprising most of the remainder (7%) of sequences.

We also provide information on viruses where we have found a particular genetic change (mutation) called E484K. This mutation is always seen in Beta (B.1.351).

Laboratory data suggest that this mutation might make it easier for a virus to infect someone again, or to infect someone who has been vaccinated, but the importance of this mutation in terms of its effect in transmitting the virus is still uncertain.

This analysis was produced by research partners at the University of Oxford. Of particular note are Dr Katrina Lythgoe, Dr David Bonsall, Dr Tanya Golubchik, and Dr Helen Fryer.

More information on how we measure variants from positive tests on the survey can be found in our blog.

The estimates provided in Sections 2 to 6 are for the percentage of the private-residential population testing positive for coronavirus (COVID-19), otherwise known as the positivity rate. We do not report the prevalence rate. To calculate the prevalence rate, we would need an accurate understanding of the swab test's sensitivity (true-positive rate) and specificity (true-negative rate).

While we do not know the true sensitivity and specificity of the test, our data and related studies provide an indication of what these are likely to be. In particular, the data suggest that the false-positive rate is very low - under 0.005%. We do not know the sensitivity of the swab test. However, other studies suggest that sensitivity (the rate of true-positive test results) may be somewhere between 85% and 98%.

You can find more information on sensitivity and specificity in our methods article and our recent blog. You can find more information on the data suggesting that our test's false-positive rate is very low in a paper written by academic partners at the University of Oxford.

The Coronavirus (COVID-19) Infection Survey analysis was produced by the Office for National Statistics (ONS) in collaboration with our research partners at the University of Oxford, the University of Manchester, Public Health England (PHE) and Wellcome Trust. Of particular note are:

• Sarah Walker - University of Oxford, Nuffield Department for Medicine: Professor of Medical Statistics and Epidemiology and Study Chief Investigator
• Koen Pouwels - University of Oxford, Health Economics Research Centre, Nuffield Department of Population Health: Senior Researcher in Biostatistics and Health Economics
• Thomas House - University of Manchester, Department of Mathematics: Reader in Mathematical Statistics

Community

In this bulletin, we refer to the number of coronavirus (COVID-19) infections within the community. Community in this instance refers to private households, and it excludes those in hospitals, care homes and/or other institutional settings.

Confidence interval

A confidence interval gives an indication of the degree of uncertainty of an estimate, showing the precision of a sample estimate. The 95% confidence intervals are calculated so that if we repeated the study many times, 95% of the time the true unknown value would lie between the lower and upper confidence limits. A wider interval indicates more uncertainty in the estimate. Overlapping confidence intervals indicate that there may not be a true difference between two estimates. For more information, see methodology page on statistical uncertainty.

Credible interval

A credible interval gives an indication of the uncertainty of an estimate from data analysis. 95% credible intervals are calculated so that there is a 95% probability of the true value lying in the interval.

False-positives and false-negatives

A false-positive result occurs when the tests suggest a person has COVID-19 when in fact they do not. By contrast, a false-negative result occurs when the tests suggest a person does not have COVID-19 when in fact they do. For more information on false-positives and false-negatives, see our methods article and our recent blog.

Reference dates

We aim to provide the estimates of positivity rate (the percentage of those who test positive) and incidence that are most timely and most representative of each week. We decide the most recent week we can report on based on the availability of test results for visits that have already happened, accounting for the fact that swabs have to be couriered to the labs, tested and results returned. On most occasions, the reference dates align perfectly, but sometimes this is not feasible. This week, the reference week is 27 June 2021 to 3 July 2021.

Within the most recent week, we provide an official estimate for positivity rate based on a reference point from the modelled trends. For positivity rates, we can include all swab test results, even from the most recent visits. Therefore, although we are still expecting further swab test results from the labs, there was sufficient data for the official estimate for infection to be based on a reference point after the start of the reference week. To improve stability in our modelling while maintaining relative timeliness of our estimates, we are reporting our official estimates based on the midpoint of the reference week. This week, the reference day for positivity rates is Wednesday 30 June 2021.

Response rates

Response rates for England, Wales, Northern Ireland and Scotland cannot be regarded as final response rates to the survey since those who are invited are not given a time limit in which to respond, and different modes of sampling are not comparable. Response rates for each nation are found in the accompanying technical dataset. We provide response rates separately for the different sampling phases of the study. Additional information on response rates can be found in our methods article.

Other Coronavirus Infection Survey (CIS) analysis and studies

This study is one of a number of studies that look to provide information around the coronavirus pandemic within the UK. For information on other studies see Section 11: Measuring the data in our previous bulletin dated 30 April 2021.

These statistics have been produced quickly in response to developing world events. The Office for Statistics Regulation, on behalf of the UK Statistics Authority, has reviewed them against several important aspects of the Code of Practice for Statistics and regards them as consistent with the Code's pillars of trustworthiness, quality and value.

The estimates presented in this bulletin contain uncertainty. There are many sources of uncertainty, including uncertainty in the test, in the estimates and in the quality of data collected in the questionnaire. Information on the main sources of uncertainty are presented in our methodology article and our blog.